BREAKING NEWS: Fortrea, a leading global contract research organization (CRO), has just announced key executive appointments that will reshape its leadership structure. Effective immediately, Oren Cohen, MD has been appointed as the new Chief Medical Officer, while Scott Dove, PhD joins as the President of Clinical Pharmacology Services. This announcement comes from the company’s headquarters in Durham, NC, on February 17, 2026.
This strategic shift signifies Fortrea’s commitment to enhancing medical strategy and scientific leadership. Dr. Cohen will now focus solely on his role as CMO, overseeing medical strategy, ethics, and governance across Fortrea’s expansive portfolio. Meanwhile, Dr. Dove will spearhead early clinical development solutions within Fortrea’s global network.
Anshul Thakral, CEO of Fortrea, emphasized the urgency of these changes, stating, “The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients.” He noted that Dr. Cohen will engage more closely in scientific dialogues and collaborate with therapeutic leaders to tackle complex development challenges.
Dr. Oren Cohen brings over 20 years of experience in drug development, having previously served as CMO and head of Clinical Pharmacology Services at Labcorp Drug Development. He has also held significant roles at Viamet Pharmaceuticals and Quintiles, now part of IQVIA. His academic credentials include an MD from Duke University and a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases.
Dr. Scott Dove adds more than 25 years of drug development experience to the Fortrea team. Most recently, he was the chief operating officer at Aravive, focusing on R&D operations in oncology. His impressive background includes leadership roles at PPD, Allergan, and Furiex Pharmaceuticals. Dr. Dove received his PhD from Texas A&M Health Science Center.
These appointments are expected to deepen Fortrea’s medical and scientific partnerships with clients, driving innovation in clinical development. As the company enhances its capabilities, it is poised to accelerate life-changing therapies for patients worldwide.
Fortrea’s commitment to excellence is reflected in its extensive experience across more than 20 therapeutic areas and a robust global network. The company continues to partner with biopharmaceutical and medical device firms, ensuring that it remains a transformative force from pipeline to patient.
Stay tuned for more updates on how these leadership changes will impact the future of clinical development at Fortrea. For additional information, visit Fortrea.com and follow the company on LinkedIn and X (formerly Twitter).
